Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen P Hunger

Showing results (111-120 of 346) with videos related to

Pageof 35
Sort By:
Pediatric Blood & Cancer|January 4, 2018
A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)Scott C Howard, Alan Davidson, Sandra Luna-Fineman, et al.
Nature Genetics|August 18, 2009
Germline genomic variants associated with childhood acute lymphoblastic leukemiaLisa R Treviño, Wenjian Yang, Deborah French, et al.
Blood|September 17, 2011
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategiesLaura E Hogan, Julia A Meyer, Jun Yang, et al.
Blood|May 6, 2010
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupKelly W Maloney, William L Carroll, Andrew J Carroll, et al.
Blood Advances|January 4, 2018
Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALLKathryn G Roberts, Yung-Li Yang, Debbie Payne-Turner, et al.
Blood|June 12, 2012
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemiaSarah K Tasian, Michelle Y Doral, Michael J Borowitz, et al.
Haematologica|February 17, 2018
MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemiaNikki A Evensen, P Pallavi Madhusoodhan, Julia Meyer, et al.
Cancer Medicine|December 24, 2017
Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232Amanda M DiNofia, Alix E Seif, Meenakshi Devidas, et al.
Blood|April 5, 2008
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyMichael J Borowitz, Meenakshi Devidas, Stephen P Hunger, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Pageof 35

Showing results (111-120 of 346) with videos related to

Sort By:
Pageof 35
Pediatric Blood & Cancer|January 4, 2018
A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)Scott C Howard, Alan Davidson, Sandra Luna-Fineman, et al.
Nature Genetics|August 18, 2009
Germline genomic variants associated with childhood acute lymphoblastic leukemiaLisa R Treviño, Wenjian Yang, Deborah French, et al.
Blood|September 17, 2011
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategiesLaura E Hogan, Julia A Meyer, Jun Yang, et al.
Blood|May 6, 2010
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupKelly W Maloney, William L Carroll, Andrew J Carroll, et al.
Blood Advances|January 4, 2018
Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALLKathryn G Roberts, Yung-Li Yang, Debbie Payne-Turner, et al.
Blood|June 12, 2012
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemiaSarah K Tasian, Michelle Y Doral, Michael J Borowitz, et al.
Haematologica|February 17, 2018
MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemiaNikki A Evensen, P Pallavi Madhusoodhan, Julia Meyer, et al.
Cancer Medicine|December 24, 2017
Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232Amanda M DiNofia, Alix E Seif, Meenakshi Devidas, et al.
Blood|April 5, 2008
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyMichael J Borowitz, Meenakshi Devidas, Stephen P Hunger, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Pageof 35